Abstract: Novel N-carboxyalkylpeptidyl compounds represented by the formula ##STR1## which are found to be useful inhibitors of matrix metalloendoproteinases which degrade major components of articular cartilage and basement membranes causing degenerative diseases such as arthritis, periodontal disease, corneal ulceration and the like, and certain cancers, are described.

Abstract: With known methods of racemizing N-acetyl-D(L)-.alpha.-amino carboxylic acids in the non-aqueous state by heating them to temperatures above room temperatures, significant quantities of by-products are formed, especially acetyl dipeptides. By converting at least a proportion of the N-acetyl-D(L)-.alpha.-amino carboxylic acids to corresponding N-acetyl-D(L)-.alpha.-amino carboxylic acid salts before or during the heating, it is possible to increase the sojourn time of the educt which is to be racemized at higher temperatures without any evident increase in the quantity of by-product formed (in particular acetylated dipeptides). Also disclosed is the production of optically active amino acids by enzymatic splitting of racemic compounds.

Abstract: Peptidomimetic compounds capable of inhibiting zinc-dependent metalloproteinases to treat pathological conditions associated with activation of endogenous metalloproteinases in mammals.

Abstract: Betaine is produced by the oxidation of a choline salt in the presence of a base and a supported noble metal catalyst at temperatures from about 20.degree. C. to 100.degree. C. and pressures from atmospheric to about 100 psi. This process is advantageous over prior processes for the production of betaine in that no amine halocarboxylate contaminants are produced by this reaction.

Abstract: A cation exchange membrane mediated acid-salt metathetic process. An aqueous salt solution is placed into a first compartment on one side of the membrane together with an organic amine extractant of limited water miscibility, and an aqueous acid solution is placed into a second compartment on the other side of the membrane. Product acid forms in the first compartment and collects in the organic amine extractant from where it is recovered. The process is particularly suitable for the recovery of a carboxylic acid from its salt.

Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.

Abstract: D- and L-.alpha.-amino acids and D- and L-.alpha.-amino aldehydes are synthesized from olefin substrates in two steps. The first step is a catalyzed asymmetric aminohydroxylation addition reaction to the olefin substrate. The addition reaction is catalyzed by osmium and is co-catalyzed by chiral ligands. The chiral ligands, in addition to being co-catalysts with the osmium, also serve to direct the addition reaction regioselectively and enantioselectively. Divalent ligands are preferred over monovalent ligands because of their enhance regio- and enantio-selectivity. As an oxidant nitrogen source for the addition reaction, either a carbamate or sulfonamide may be employed. If carbamate is employed as an oxidant nitrogen source, the resultant .beta.-hydroxycarbamate is deprotected to yield the corresponding .beta.-hydroxyamine. If sulfonamide is employed as an oxidant nitrogen source, the resultant .beta.-hydroxysulfonamide is deprotected to yield the corresponding .beta.-hydroxyamine. The resultant .beta.

Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.

Abstract: Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each preferably independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; Q is preferably --C(O)--; R.sub.B is preferably iso-butyl; R.sub.A is --(T).sub.m --(D).sub.m --R.sub.1, in which T is preferably oxygen or NH, m is 0 or 1, and D is preferably C.sub.1-4 alkyl or C.sub.2-4 alkenyl; and X is preferably an aldehyde, .alpha.-ketoester or .alpha.-ketoamide.

Abstract: In a process and an apparatus for the continuous preparation of N-acylamino carboxylic acids and N-acylamino sulfonic acids, and their alkali metal salts, from the alkali metal salts of amino carboxylic acids and amino sulfonic acids, respectively, and carbonyl halides in a reactor designed as circulating circuit, the reactants are fed for immediate reaction into the circulating circuit, and a part of the product solution corresponding to the amount fed in is continuously discharged from the circulating circuit. The reactants are circulated by a circulating pump. The temperature in the reactors is controlled. The heat produced in the reaction is removed.

Abstract: This invention relates to lyoprotection agents for protecting macromolecules during lyophilization or freeze-drying. In particular, methods for use of these lyoprotectants in conjugate formulations are disclosed. Additionally, this invention describes lyophilized instant kit formulations for the radiolabeling of pharmaceuticals and/or macromolecules.

Abstract: Compounds of the formula (1) ##STR1## wherein X and Y are each N or NH, Z is O or OH, (1) when X=N and Y=NH, Z=O, and *1 and *3 are double bonds, (2) when X=NH and Y=N, Z=O, and *2 and *3 are double bonds, (3) when X=N and Y=N, Z=OH, and *2 and *4 are double bonds, and R is a side chain derived from an amino acid; for example, the amino acid is glycine with R=H, alanine with R=CH.sub.3, glutamic acid with R=CH.sub.2 CH.sub.2 COOH, lysine with R=CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 NH.sub.2, or leucine with R=CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, and/or an analogues thereof are useful for imparting a "thick, sour" taste to foods.

Abstract: Novel N-carboxyalkylpeptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.

Abstract: Betaine is produced by the oxidation of a choline salt in the presence of a supported noble metal catalyst at temperatures from about 20.degree. C. to 100.degree. C. and pressures from atmospheric to about 100 psi. This process is advantageous over prior processes for the production of betaine in that no amine halocarboxylate contaminants are produced by this reaction.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.

Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; RB is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.

Abstract: N-acylamino carboxylic acids and N-acylamino sulfonic acids and their alkali metal salts from the technical alkali metal salts of amino carboxylic acids and amino sulfonic acids, respectively, with an active content of 50-95% by weight, based on the solids content of the technical alkali metal salts, and from alkyl carboxylates, are prepared by(a) preparing a suspension of the solid anhydrous technical alkali metal salts of the amino carboxylic acids or amino sulfonic acids in the alkyl carboxylates,(b) reacting this suspension by adding more than 30 to 150 mol % of strong bases to give the alkali metal salts of the N-acylamino carboxylic acids or N-acylamino sulfonic acids, and(c) if required preparing therefrom the free N-acylamino carboxylic acids or N-acylamino sulfonic acids in a conventional way by adding acids.

Abstract: New fluorinated derivatives useful as surfactants or in the transport of drug or markers, or in drug targeting, and preparations containing the derivatives, for medical, cosmetic and veterinary uses, having the formula: ##STR1## wherein R.sub.F is a fluorinated radical, X is a linear or branched alkylene, R.sup.1 is H or CH.sub.3, R.sup.2 is a radical having at least one OH group, R.sup.3 is a radical derived from an amino acid or a peptide, 1.ltoreq.n.ltoreq.50 and 0.ltoreq.m.ltoreq.200 with 0.2.ltoreq.n/n+m.ltoreq.1.These derivatives can be used as prodrugs or in formulating pharmaceutical, cosmetic and veterinary preparations, in biology and medicine, notably in compositions acting as carriers of oxygen and other gases, of contrast agents, or as carriers of substances used in therapy, or as carriers of markers.

Abstract: A process is disclosed for the preparation of N.sup.G -monoalkyl-L-arginine and related compounds and salts thereof, for example N.sup.G -monomethyl-L-arginine by reacting N-alkylaminoiminomethane sulphonic acid of formula (II) with an amino acid of formula (III).

Abstract: A process for the preparation of aminoacetic acids or aminoacetonitriles with a tertiary hydrocarbon radical in the .alpha.-position in which monoamide derivatives of malonic acid are subjected to a Hofmann rearrangement.

Abstract: Heterocyclic acyldipeptides of the formula I ##STR1## wherein Z represents an oxygen or sulphur atom or a --CH.sub.2 -group;R.sub.1, R.sub.2 and R.sub.3 individually represent hydrogen or certain organic groups;R.sub.4 and R.sub.5, which are identical or different, represent an OR.sub.6 or NHR.sub.6 group, wherein R.sub.6 is hydrogen or certain organic groups;Y represents a --CH.sub.2 --, .dbd.CH-- or .dbd.N-- group;A represents a --(CH.sub.2).sub.3 -- group when Y is --CH.sub.2 --, the two rings being transcondensed, or a ##STR2## wherein R.sub.7 represents H, F, Br, Cl, nitro, or certain organic groups when Y is .dbd.CH-- or .dbd.N--; and their pharmaceutically acceptable salts are provided. These heterocyclic acyldipeptides and their salts are useful as active compounds in medicaments having immunostimulatory and antitumor activity.

Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m--(D).sub.m--R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide or aldehyde.

Abstract: A novel amino acid derivative represented by the general formula (I) shown below or a salt thereof have now been provided by chemical synthesis, and it has been found that these new compounds stimulate proliferation and physiological activities of the T cells of mammals, have an immunomodulating activity and also have an antitumor activity or a carcinostatic activity. It has also been found that these new compounds have an effect of stimulating the proliferation of hematopoietic stem cells. ##STR1## wherein y is 0 or 1; R.sup.1 represents an unsubstituted C.sub.1 -C.sub.8 alkyl group or others;R.sup.2 represents a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group or others;R.sup.3 represents a hydrogen atom, a C.sub.1 -C.sub.8 alkyl group or others;R.sup.4 represents a hydrogen atom, a C.sub.1 -C.sub.3 alkyl group or others;R.sup.5 represents a group --OR.sup.42, a group ##STR2## or others.

Abstract: A compound of the formula ##STR1## is disclosed. X is selected from the group consisting of aryl, alkyl, imte ester, imino ester, amidine, azide, isocyanate, and dithiocarbonate. R' is a group selected from the group consisting of groups containing a hydroxyl moiety, groups containing a protected hydroxyl moiety, and groups containing an O-linked sugar. G is a carbon chain of 0-10 carbons and R is not a methyl group and is a group capable of removal under conditions compatible with glycopeptide synthesis. In a preferred form the compound, R is selected from the group consisting of benzylic or allyl groups and X is CPh.sub.2. A method of forming a glycocide from the compound is also disclosed.

Abstract: A method is provided for preparing decapeptide and undecapeptide derivatives of LHRH by solution phase peptide chemistry as well as intermediate peptides useful in the same method.

Abstract: Process for producing high purity aqueous solutions of betaine by reaction of substantially equal molar ratios of trimethylamine and an alkaline salt of monochloroacetic acid in aqueous solution.

Abstract: The present invention relates to a process for preparing protected amines or amino acids. The invention furthermore relates to the use of tocopheryl radicals or radicals derived therefrom as protective groups for amines and amino acids, and to compounds obtained in this process as intermediates and to processes for preparing dipeptides and oligopeptides.

Abstract: A process for the combined synthesis of betaine and choline chloride from monochloroacetic acid, trimethylamine and ethylene oxide by first reacting trimethylamine with monochloroacetic acid, and then reacting ethylene oxide with the reaction product from the previous step.

Abstract: The invention concerns the discovery of the surprising and unexpected therapeutic effects of hydroxyl ions. The observed medicinal properties of these ions are both novel and broad in scope. The acute corrosive effects and toxicity of hydroxyl ions on living tissue has previously overwhelmed their therapeutic attributes. Unique hydroxyl ion modulating compounds have been discovered and are within the scope of the invention. When used appropriately as companions with hydroxyl ions, these modulating compounds obviate and attenuate the harmful effects of hydroxyl ions, unmasking and revealing their previously unknown and undemonstratable therapeutic properties. These hydroxyl ion modulating compounds do not significantly interfere with the surprising and unexpected therapeutic benefits of the hydroxyl ions. The novel hydroxyl ion modulating compounds are generally characterized as N,N-disubstituted-aminoalkanoate salts and substituted N,N-substituted-aminoalkanoate salts.

Abstract: The direct saponification of methionine nitrile obtained from methylmercaptopropionaldehyde, prussic acid and ammonia gives low yields, catalyst and educt losses and unwanted side-products. The aim of the invention is therefore to provide a method which can be carried out without isolating the intermediate products, in particular continuously, and with low losses. The ketone used is recovered in high yields after amide saponification since this liberates the ketone from side-products. In order to recover the ammonia, it is necessary for the ammonia to be substantially freed of ketone, the mixture of ammonia, ketone and water obtained being separated under pressure in a separation column. When the amide is saponified at .gtoreq.160.degree. C., amide concentrations of less than 25% by wt. are preferred. Methionine nitrile is produced by treatment with at least 4 equivalents of .gtoreq.50% by wt. ammonia at between 40.degree. and 80.degree. C./or between 5 and 60 min.

Abstract: Amino acid esters of the formulas ##STR1## wherein m is zero or one and R.sub.3 is an acid protecting group are prepared. These amino acid esters are useful as intermediates in the preparation of fused bicyclic ring compounds.

Abstract: Esters or amides of a peptide, preferably a dipeptide, consisting essentially of natural or synthetic L-amino acids with hydrophobic side chains were found to have specific cellular toxicities. Preferable amino acids of the peptide are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-leucyl L-isoleucine, L-phenylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine, glycyl L-phenylalanine and L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.

Abstract: Pharmaceutical compositions containing FSH, LH or hCG stabilized by means of a combination of sucrose and glycine. The formulation is particularly suitable for stabilizing a lyophilisate of recombinant gonadotropins.

Abstract: Disclosed are water-insoluble, calcium or magnesium salts of alpha amino acids and a process for their preparation. The process comprises the steps of reacting an alpha-amino-protected alkyl ester of an amino acid with a metal base, thereby forming a water-soluble amino acid salt, followed by reacting the water-soluble salt with either a calcium or magnesium salt, resulting in the formation of a water-insoluble salt of the amino acid. The water-insoluble salts can be used as feed supplements for ruminant animals and to supplement food products for human consumption.

Abstract: The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), ##STR1## and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diagnostics.

Abstract: Therapeutic agents and methods for the treatment of immunologically mediated diseases and malignancies of myeloid cell or lymphoid cell origin. These particular methods utilize the characterization of particular activation mechanisms important to the progression of these pathologies in humans. Selective inhibition of cell types responsible for precipitating these disorders in humans are provided with therapeutic agents which include peptides capable of inhibiting dipeptidyl peptidase-I activation of proenzymes present primarily in cytotoxic T-cells and myeloid cells, such as Gly--Phe--CHN.sub.2. Antisense oligonucleotides are also characterized which are specific for human dipeptidyl peptidase-I gene which may be used in the treatment of the described disorders.

Abstract: The invention concerns the discovery of the surprising and unexpected therapeutic effects of hydroxyl ions. The observed medicinal properties of these ions are both novel and broad in scope. The acute corrosive effects and toxicity of hydroxyl ions on living tissue has previously overwhelmed their therapeutic attributes. Unique hydroxyl ion modulating compounds have been discovered and are within the scope of the invention. When used appropriately as companions with hydroxyl ions, these modulating compounds obviate and attenuate the harmful effects of hydroxyl ions, unmasking and revealing their previously unknown and undemonstratable therapeutic properties. These hydroxyl ion modulating compounds do not significantly interfere with the surprising and unexpected therapeutic benefits of the hydroxyl ions. The novel hydroxyl ion modulating compounds are generally characterized as N,N-disubstituted-aminoacetate salts and substituted N,N-substituted-aminoacetate salts.

Abstract: A process for the isolation of L-leucine and L-isoleucine from an aqueous solution containing these amino acids and their separation from each other by contacting the solution with a zeolite under acid conditions.

Abstract: The invention concerns the discovery of the surprising and unexpected therapeutic effects of hydroxyl ions. The observed medicinal properties of these ions are both novel and broad in scope. The acute corrosive effects and toxicity of hydroxyl ions on living tissue has previously overwhelmed their therapeutic attributes. Unique hydroxyl ion modulating compounds have been discovered and are within the scope of the invention. When used appropriately as companions with hydroxyl ions, these modulating compounds obviate and attenuate the harmful effects of hydroxyl ions, unmasking and revealing their previously unknown and undemonstratable therapeutic properties. These hydroxyl ion modulating compounds do not significantly interfere with the surprising and unexpected therapeutic benefits of the hydroxyl ions. The novel hydroxyl ion modulating compounds are generally characterized as N,N-disubstituted-aminoacetate salts and substituted N,N-substituted-aminoacetate salts.

Abstract: The present invention relates to a tripepride having the amino acid sequence Alanine-lsoleucine-Phenylalanine. This invention also relates to methods and compositions for inhibiting growth of dental plaque on tissues within an oral cavity of a human or other animal comprising topical administration, to tissues of such oral cavity, of a composition comprising a safe and effective amount of the tripepride.

Abstract: Peptides having the formula: ##STR1## inhibit the binding of endothelin and are useful in treating diseases associated with excess production or secretion of endothelin.

Abstract: This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.

Abstract: A method for producing an aqueous solution of an aminocarboxylic acid from an aqueous solution of an alkali metal salt of the aminocarboxylic acid is disclosed. The first step of the method is to adjust the pH of the aqueous solution of the alkali metal salt of the aminocarboxylic acid to between about 1.0 and about 3.0. This is done by adding a monovalent inorganic acid to the aqueous solution of the alkali metal salt of the aminocarboxylic acid to form an aqueous feed solution containing protonated aminocarboxylic acid and an inorganic alkali salt having an inorganic anion and an alkali metal cation. The second step of the method is to pass the aqueous feed solution through at least one membrane using a diafiltration process to separate the aqueous feed solution into an aqueous permeate solution, containing the alkali metal cation, and an aqueous retentate solution containing the aminocarboxylic acid.

Abstract: A compound of the formula ##STR1## is disclosed. X is selected from the group consisting of aryl, alkyl, imidate ester, imino ester, amidine, azide, isocyanate, and dithiocarbonate. R' is a group selected from the group consisting of groups containing a hydroxyl moiety, groups containing a protected hydroxyl moiety, and groups containing an O-linked sugar. G is a carbon chain of 0-10 carbons and R is not a methyl group and is a group capable of removal under conditions compatible with glycopeptide synthesis. In a preferred form the compound, R is selected from the group consisting of benzylic or allyl groups and X is CPh.sub.2. A method of forming a glycocide from the compound is also disclosed.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is aryl, or a group of the formula: ##STR2## wherein X is CH or N, and Z is O or N--R.sup.5,in which R.sup.5 is hydrogen or lower alkyl,R.sup.2 is hydroxy or lower alkoxy,R.sup.3 is hydrogen or lower alkyl which may have suitable substituent(s),R.sup.4 is ar(lower)alkyl which may have suitable substituent(s),A is carbonyl or sulfonyl, andY is a bond or lower alkenylene,and pharmaceutically acceptable salt thereof. The disclosed compounds are useful for treating respiratory diseases such as bronchaedema.

Abstract: A prophylactic or therapeutic agent for malignant hypercalcemia, bone Paget's disease and osteoporosis is disclosed, which contains as an active ingredient a dipeptide derivative represented by formula:R.sup.1 NH--CH(R.sup.2)--CO--NH--CH(R.sup.3)--R.sup.4 (I)wherein R.sup.1 represents an aliphatic acyl group, a halogen-substituted aliphatic acyl group, or benzyloxycarbonyl group; R.sup.2 represents a lower alkyl group or an aralkyl group; R.sup.3 represents a lower alkyl group, an aralkyl group, or methylthioethyl group; R.sup.

Abstract: This invention relates to novel arginine aldehydes, their salts and hydrates, which compounds selectively exhibit serine proteases inhibitory activity, are highly stable in aqueous solutions, and are useful for anti-trypsin and anti-thrombin activity.

Abstract: The process described relates to the preparation of aqueous betaine solutions by reaction of a tertiary amine with an .omega.-monohalocarboxylic acid, preferably monochloroacetic acid, and an alkali metal hydroxide in the presence of water, which solutions are said to be highly pure particularly in respect of the tertiary starting amine and .omega.-monohalocarboxylic acid. This is achieved by first reacting the three reaction components in a certain molar ratio with the aim of obtaining a betaine solution which comprises only a tolerated amount of starting amine. This aqueous betaine solution is then treated with a sulfonating agent, preferably with an alkali metal sulfite, alkali metal pyrosulfite or alkali metal bisulfite, for conversion of the .omega.-monohalocarboxylic acid present into the corresponding sulfocarboxylic acid, which is not troublesome. The process described is simple to carry out and leads to the highly pure aqueous betaine solutions mentioned.

Abstract: Glycine and sodium sulfate decahydrate are separated from a starting aqueous solution containing glycine, sodium sulfate, and impurities, by forming a slurry which is a solid mixture of glycine and sodium sulfate decahydrate, followed by separation of the mixed crystals.